Skip to main content
. 2015 Nov 6;10(11):e0142350. doi: 10.1371/journal.pone.0142350

Table 4. Peripheral NK-cells, T-cells and naive T-cells per CHARGE patient.

Patient NK-cells 1 CD3+ T-cells 1 CD4+ T-cells 1 Naive mature CD4+ T-cells 2 Naive mature CD4+ T-cells 2 CD8+ T-cells 1 Naive mature CD8+ T-cells 2 Naive mature CD8+ T-cells 2
CD16+56+ CD45+ CD3+ CD3+ CD4+ CD45R0- CCR7+ CD27+ CD28+ CD45R0- CCR7+ CD27+ CD28+ CD3+ CD8+ CD45R0- CCR7+ CD27+ CD28+ CD45R0- CCR7+ CD27+ CD28+
CHD01 261 (100–700) 1628 (1000–2000) 884 (500–1300) 527 (277–796) 59.6% (42.4–66.3) 578 (300–800) 396 (205–465) 68.5% (48.8–72.9)
CHD02 584 (100–600) 1755 (1100–2800) 1209 (500–1800) 800 (515–913) 66.2% (60.2–74.6) 446 (400–1200) 261 (369–578) 58.6% (49.1–78.8)
CHD04 117 (100–700) 2010 (1400–3600) 1322 (700–2000) 1000 (n/a) 75.7% (n/a) 500 (500–1400) 405 (n/a) 81.1% (n/a)
CHD05 88 (100–700) 1641 (1000–2000) 1001 (500–1300) 629 (277–796) 62.8% (42.4–66.3) 452 (300–800) 273 (205–465) 60.3% (48.8–72.9)
CHD06 110 (100–400) 1110 (700–1900) 610 (400–1300) 338 (277–796) 55.4% (42.4–66.3) 250 (200–700) 147 (205–465) 58.6% (48.8–72.9)
CHD08 230 (100–700) 1285 (1000–2000) 732 (500–1300) 394 (277–796) 53.8% (42.4–66.3) 392 (300–800) 229 (205–465) 58.4% (48.8–72.9)
CHD09 467 (100–700) 1458 (1400–3600) 862 (700–2000) 553 (n/a) 64.2% (n/a) 417 (500–1400) 325 (n/a) 77.9% (n/a)
CHD10 957 (100–700) 2546 (1400–3600) 1488 (700–2000) 1019 (n/a) 68.5% (n/a) 813 (500–1400) 236 (n/a) 29.1% (n/a)
CHD11 234 (100–700) 1282 (1000–2000) 845 (500–1300) 488 (277–796) 57.8% (42.4–66.3) 340 (300–800) 198 (205–465) 58.4% (48.8–72.9)
CHD12 182 (100–600) 1374 (1100–2800) 915 (500–1800) 390 (515–913) 42.7% (60.2–74.6) 357 (400–1200) 115 (369–578) 32.2% (49.1–78.8)
CHD13 372 (100–600) 2192 (1100–2800) 1269 (500–1800) 814 (515–913) 64.2% (60.2–74.6) 652 (400–1200) 247 (369–578) 37.9% (49.1–78.8)
CHD14 330 (100–600) 899 (1100–2800) 458 (500–1800) 215 (515–913) 47.0% (60.2–74.6) 297 (400–1200) 87 (369–578) 29.3% (49.1–78.8)
CHD15 172 (100–700) 1110 (1000–2000) 787 (500–1300) 490 (277–796) 62.3% (42.4–66.3) 250 (300–800) 138 (205–465) 55.5% (48.8–72.9)
CHD16 184 (100–700) 1042 (1000–2000) 308 (500–1300) 111 (277–796) 36.2% (42.4–66.3) 649 (300–800) 115 (205–465) 17.7% (48.8–72.9)
CHD17 118 (100–700) 1622 (1400–3600) 894 (700–2000) 691 (n/a) 77.3% (n/a) 520 (500–1400) 79 (n/a) 71.8% (n/a)
CHD18 219 (100–1100) 1483 (2200–5500) 1008 (1100–3600) 725 (n/a) 72.0% (n/a) 373 (500–1800) 310 (n/a) 83.2% (n/a)
CHD19 303 (100–700) 887 (1000–2000) 507 (500–1300) 250 (277–796) 49.3% (42.4–66.3) 230 (300–800) 94 (205–465) 41.0% (48.8–72.9)
CHD20 580 (100–600) 940 (1100–2800) 400 (500–1800) 138 (515–913) 34.5% (60.2–74.6) 290 (400–1200) 73 (369–578) 25.1% (49.1–78.8)
CHD21 187 (100–700) 1455 (1000–2000) 917 (500–1300) 654 (277–796) 71.4% (42.4–66.3) 417 (300–800) 310 (205–465) 74.6% (48.8–72.9)
CHD22 354 (100–700) 1431 (1400–3600) 1035 (700–2000) 602 (n/a) 58.1% (n/a) 182 (500–1400) 102 (n/a) 56.2% (n/a)
CHD23 192 (100–600) 1239 (1100–2800) 734 (500–1800) 495 (515–913) 67.5% (60.2–74.6) 365 (400–1200) 265 (369–578) 72.8% (49.1–78.8)
CHD25 98 (100–700) 1404 (1400–3600) 896 (700–2000) 625 (n/a) 69.7% (n/a) 422 (500–1400) 315 (n/a) 74.7% (n/a)
CHD26 656 (100–700) 1261 (1000–2000) 775 (500–1300) 511 (277–796) 65.9% (42.4–66.3) 342 (300–800) 143 (205–465) 41.9% (48.8–72.9)
CHD27 452 (100–700) 606 (1000–2000) 368 (500–1300) 109 (277–796) 29.5% (42.4–66.3) 169 (300–800) 7 (205–465) 4.1% (48.8–72.9)

1 Absolute numbers in cells/μl. Age-matched reference values are shown in brackets [13,15]. Values below the age-matched reference values are shown in bold.

2 Absolute numbers in cells/μl and relative numbers in percentages of naive mature CD4+ or CD8+ T-cells. Age-matched reference values are shown in brackets [15]. If both the absolute and the relative numbers are below the age-matched reference values, values are shown in bold.

n/a, age-matched reference value not available